Bristol-Myers Squibb (NYSE:BMY) Q3 results:
Revenues: $6,007M (+5.6%); product sales: $5,768M (+6.2%).
Key product sales: Eliquis: $1,928M (+22.3%); Opdivo: $1,817M (+1.3%); Orencia: $767M (+13.6%); Sprycel: $558M (+13.6%); Yervoy: $353M (-7.6%).
Net income: $1,366M (-28.6%); EPS: $0.83 (-28.4%); non-GAAP EPS: $1.17 (+7.3%).
2019 guidance: EPS: $3.46 – 3.56 from $3.73 – 3.83; non-GAAP EPS: $4.25 – 4.35 from $4.20 – 4.30.
Shares up 1% premarket.
Previously: Bristol-Myers Squibb EPS beats by $0.10, beats on revenue (Oct. 31)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.